Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 2, 2003 - Issue 3
Submit an article Journal homepage
41
Views
12
CrossRef citations to date
0
Altmetric
Review

Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era

Terry A Jacobson Director, Office of Health Promotion and Disease Prevention, Department of Medicine, Emory University School of Medicine, Thomas K Glenn Memorial Building, 69 Jessie Hill Jr Drive, Atlanta, GA 30303, USA
Pages 269-286 | Published online: 03 Mar 2005

Bibliography

  • SHEPHERD J, BLAUW GJ, MURPHY MB et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 360:1623–1630.
  • NO AUTHORS LISTED: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7–22.
  • NO AUTHORS LISTED: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA (2001) 285:2486–2497.
  • NO AUTHORS LISTED: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl. J. Med. (1998) 339:1349–1357.
  • DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA (1998) 279:1615–1622.
  • SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. (1996) 335:1001–1009.
  • SHEPHERD J, COBBE SM, FORD I et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl. J. Med. (1995) 333:1301–1307.
  • NO AUTHORS LISTED: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
  • PASTERNAK RC, SMITH SC Jr, BAIREY-MERZ CN et al: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J. Am. Coll. Cardiol. (2002) 40:568–573.
  • JACOBSON TA, GRIFFITHS GG, VARAS C et al: Impact of evidence-based 'clinical judgment' on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. Arch. Intern. Med. (2000) 160:1361–1369.
  • FOOT DK, LEWIS RP, PEARSON TA et al.: Demographics and cardiology, 1950–2050.1 Am. Coll. Cardiol. (2000) 35:B66–B80.
  • JACOBSON TA: Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century. Curr. Atheroscler. Rep. (2001) 3:373–382.
  • •A general overview of clinical trials utilising combination lipid-lowering therapy. Reports trials combining statins with fibrates, niacin, and bile acid sequestrants.
  • DAVIDSON MH: Combination therapyfor dyslipidemia: safety and regulatory considerations. Am. J. Cardiol. (2002) 90:K50–K60.
  • OMAR MA, WILSON JP: FDA adverse event reports on statin-associated rhabdomyolysis. Ann. Pharmacother. (2002) 36:288–295.
  • ••Retrospective review of US and other cases ofstatin-induced rhabdomyolysis reported to the FDA between 1997–2000. Highlights potential drug interactions in 60% of cases.
  • UCAR M, MJORNDAL T, DAHLQVIST R: HMG-CoA reductase inhibitors and myotoxicity. Drug Sal: (2000) 22:441–457.
  • GOLDMAN JA, FISHMAN AB, LEE JEet al.: The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. Arthritis Rheum. (1989) 32:358–359.
  • WILLIAMS D, FEELY J: Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clio. Pharmacy/dna. (2002) 41:343–370.
  • HAMILTON-CRAIG I: Statin-associated myopathy. Med. I Aust. (2001) 175:486–489.
  • PEDERSEN TR, BERG K, COOK TJ et al: Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch. Intern. Med. (1996) 156:2085–2092.
  • BAKER SK, TARNOPOLSKY MA: Statin myopathies: pathophysiologic and clinical perspectives. Clio. Invest. Med. (2001) 24:258–272.
  • •Provides a theoretical model for statin-induced myopathy.
  • PHILLIPS PS, HAAS RH, BANNYKH S et al.: Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med. (2002) 137:581–585.
  • •Describes a case series of statin-induced myopathy and muscle changes on biopsy without significant CK changes.
  • OMAR MA, WILSON JP, COX TS: Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann. Pharmacother. (2001) 35:1096–1107.
  • •Good overview of rhabdomyolysis, including its presentation, diagnosis, and treatment.
  • GROB D: Rhabdomyolysis and drug-related myopathies. Curr. Opin. Rheumatol (1990) 2:908–915.
  • PRENDERGAST BD, GEORGE CF: Drug-induced rhabdomyolysis - mechanisms and management. Postgrad. Med. J. (1993) 69:333–336.
  • POELS PJ, GABREELS FJ: Rhabdomyolysis: a review of the literature. Cbh. Neural Neurosurg. (1993) 95:175–192.
  • BERTOLINI S, BON GB, CAMPBELL LM et al: Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis (1997) 130:191–197.
  • DART A, JERUMS G, NICHOLSON G et al: A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am. J. Cardial (1997) 80:39–44.
  • LAMBRECHT LJ, MALINI PL: Efficacy and tolerability of simvastatin 20 mg versus pravastatin 20 mg in patients with primary hypercholesterolemia. European Study Group. Acta Cardial (1993) 48:541–554.
  • FARMER JA, TORRE-AMIONE G: Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Sal: (2000) 23:197–213.
  • SIMES J, FURBERG CD, BRAUNWALD E et al: Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur. Heart J. (2002) 23:207–215.
  • DUJOVNE CA, CHREMOS AN, POOL JL et al.: Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. Am. J. Med. (1991) 91:S25–S30.
  • BLACK DM, BAKKER-ARKEMA RG, NAWROCKI JW: An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch. Intern. Med. (1998) 158:577–584.
  • SCHWARTZ GG, OLSSON AG, EZEKOWITZ MD et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 285:1711–1718.
  • JOKUBAITIS LA: Updated clinical safetyexperience with fluvastatin. Am. J. Card/al (1994) 73:D18–D24.
  • SERRUYS PW, DE FAYER P, MACAYA C etal, for the Lescol Intervention Prevention Study Investigators: fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA (2002) 256:3215–3222.
  • STAFFA JA, CHANG J, GREEN L: Cerivastatin and reports of fatal rhabdomyolysis. N Engl. J. Med. (2002) 346:539-540. Letter.
  • ••FDA report from May 2001 of the totalUS cases of fatal rhabdomyolysis reported, adjusted by the estimated number of prescriptions written.
  • CORSINI A, BELLOSTA S, BAETTA R et al.: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. (1999) 84:413–428.
  • ••One of the best review papers to summarisethe differences among statins in pharmacoltinetics. Provides insight and rationale of possible differences in statin drug interactions.
  • LANE RJ, MASTAGLIA FL: Drug-induced myopathies in man. Lancet (1978) 2:562–566.
  • FICHTL B, KURZ H: Binding of drugs tohuman muscle. Eur. j Clin. Pharmacol. (1978) 14:335–340.
  • LANG JE, WANG P, GLUECK CJ: Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism. Clin. Chim. Acta (1996) 254:65–92.
  • HINO I, AKAMA H, FURUYA T et al: Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease. Arthritis Rheum. (1996) 39:1259–1260.
  • BERTZ RJ, GRANNEMAN GR: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Cbh. Pharmacakinet. (1997) 32:210–258.
  • WRIGHTON SA, VANDENBRANDEN M, RING BJ: The human drug metabolizing cytochromes P450.1 Pharmacakinet. Biopharm. (1996) 24:461–473.
  • HERMAN RJ: Drug interactions and thestatins. CMAJ(1999) 161:1281–1286.
  • SHIMADA T, YAMAZAKI H, MIMURA M et al.: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. (1994) 270:414–423.
  • THUMMEL KE, SHEN DD, PODOLL TD et al.: Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J. Pharmacol. Exp. Ther. (1994) 271:557–566.
  • MIETTINEN TA, GYLLING H, STRANDBERG T et al: Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. Br Med. J. (1998) 316:1127–1130.
  • REINOSO RE SANCHEZ NA, GARCIA MJ et al: Pharmacokinetic interactions of statins. Methods Find. Esp. Clin. Pharmacol. (2001) 23:541–566.
  • •Comprehensive review of individual statin drug interactions.
  • MILLER DB, SPENCE JD: Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacakinet. (1998) 34:155–162.
  • SHEK A, FERRILL MJ: Statin-fibrate combination therapy. Ann. Pharmacother. (2001) 35:908–917.
  • WEN X, WANG JS, BACKMAN JT et al: Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab. Dispos. (2001) 29:1359–1361.
  • PRUEKSARITANONT T, ZHAO JJ, MA B et al.: Mechanistic studies on metabolic interactions between gemfibrozil and statins. I Pharmacol. Exp. Ther. (2002) 301:1042–1051.
  • ••Important paper describing new mechanisticinteractions between statins and gemfibrozil. Offers a possible explanation for the increased myottedcity and rhabdomyolysis of cerivastatin with gemfibrozil.
  • PRUEKSARITANONT T, SUBRAMANIAN R, FANG X et al: Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos. (2002) 30:505–512.
  • EVANS M, REES A: The myotoxicity ofstatins. Cum: Opin. Lipidal (2002) 13:415–420.
  • MU YM, YANASE T, NISHI Y et al: Combined treatment with specific ligands for PPARgamma:RXR nuclear receptor system markedly inhibits the expression of cytochrome P450arom in human granulosa cancer cells. Ma Cell Eric/or/Ma (2001) 181:239–248.
  • KATSILAMBROS N, BRAATEN J, FERGUSON BD et al: Muscular syndrome after clofibrate. N Engl. j Med. (1972) 286:1110–1111.
  • SEKOWSKI I, SAMUEL P: Clofibrate-induced acute muscular syndrome. Am. J. Cardiol (1972) 30:572–574.
  • AAKHUS S, DAHL K, WIDEROE TE: Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial. Transplant. (1999) 14:648–654.
  • BRUNNER FP, FASSBINDER W, BROYER M et al.: Survival on renal replacement therapy: data from the EDTA Registry. Nephrol Dial. Transplant. (1988) 3:109–122.
  • KLINTMALM GB, IWATSUKI S, STARZL TE: Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation (1981) 32:488–489.
  • NO AUTHORS LISTED: Sandimmune® (cyclosporine). Novartis US prescribing information. In: Physicians' Desk Reference (56th edn). Medical Economics, Montvale, NJ (2002):2388–2391.
  • AKHLAGHI E MCLACHLAN AJ, KEOGH AM et al: Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br j Clin. Pharmacol (1997) 44:537–542.
  • DUGGAN DE, VICKERS S: Physiological disposition of HMG-CoA-reductase inhibitors. Drug Metab. Rev (1990) 22:333–362.
  • TOBERT JA: Efficacy and long-term adverse effect pattern of lovastatin. Am. J. Cardiol (1988) 62:J28–J34.
  • REAVEN E WITZTUM JL: Lovastatin, nicotinic acid, and rhabdomyolysis. Ann. Intern. Med. (1988) 109:597–598.
  • GUPTA EK, ITO MK: Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. Heart Dis. (2002) 4:124–137.
  • OLBRICHT C, WANNER C, EISENHAUER T et al: Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin. Pharmacol Ther. (1997) 62:311–321.
  • EAST C, ALIVIZATOS PA, GRUNDY SM et al.: Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl. J. Med. (1988) 318:47–48.
  • GULLESTAD L, NORDAL KE BERG KJ et al.: Interaction between lovastatin and cyclosporine A after heart and kidney transplantation. Transplant. Proc. (1999) 31:2163–2165.
  • KYRKLUND C, BACKMAN JT, KIVISTO KT et al.: Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol Ther. (2001) 69:340–345.
  • KIVISTO KT, KANTOLA T, NEUVONEN PJ: Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br j Clin. Pharmacol (1998) 46:49–53.
  • GRUNDEN JW, FISHER KA: Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann. Pharmacother. (1997) 31:859–863.
  • HORN M: Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. Arch. Dermatol (1996) 132:1254.
  • NEUVONEN PJ, JALAVA KM: Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Pharmacol Ther. (1996) 60:54–61.
  • LEES RS, LEES AM: Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl. Med. (1995) 333:664–665.
  • AYANIAN JZ, FUCHS CS, STONE RM: Lovastatin and rhabdomyolysis. Ann. Intern. Med. (1988) 109:682–683.
  • AZIE NE, BRATER DC, BECKER PA et al.: The interaction of diltiazem with lovastatin and pravastatin. Clin. Pharmacol Ther. (1998) 64:369–377.
  • BALLANTYNE CM, RADOVANCEVIC B, FARMER JA et al.: Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. j Am. Coll. Cardiol (1992) 19:1315–1321.
  • KANDUS A, KOVAC D, KOSELJ M et al.: Lovastatin treatment of hyperlipidemia in kidney transplant recipients on cyclosporine immunosuppression. Transplant. Proc. (1994) 26:2642–2643.
  • TRAINDL 0, READING S, FRANZ M et al.: Low-dose lovastatin in hyperlipidemic kidney graft recipients with cyclosporine A. Transplant. Proc. (1992) 24:2745–2747.
  • KOBASHIGAWA JA, MURPHY FL, STEVENSON LW et al.: Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation (1990) 82:IV281-1V283.
  • NO AUTHORS LISTED: Mevacor® (lovastatin). Merck US prescribing information. In: Physicians' Desk Reference (56th edn). Medical Economics, Montvale, NJ (2002):2132–2136.
  • GRUER PJ, VEGA JM, MERCURI MF et al: Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am. J. Cardiol (1999) 84:811–815.
  • ARNADOTTIR M, ERIKSSON LO, THYSELL H et al.: Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron (1993) 65:410–413.
  • KANTOLA T, KIVISTO KT, NEUVONEN PJ: Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. (1998) 64:177–182.
  • GILAD R, LAMPL Y: Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clip. Neuropharmacol (1999) 22:295–297.
  • MOGYOROSI A, BRADLEY B, SHOWALTER A et al: Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. Intern. Med. (1999) 246:599–602.
  • NO AUTHORS LISTED: Zocor® (simvastatin). Merck US prescribing information. In: Physicians' Desk Reference (56th edn). Medical Economics, Montvale, NJ (2002):2219–2223.
  • ORLOFF DG: Supplemental NDA 19-766/S-051 (May 6, 2002 correspondence with Merck & Co., Inc.).
  • NO AUTHORS LISTED: Lipitor® (atorvastatin calcium). Pfizer US prescribing information. In: Physicians' Desk Reference (56th edn). Medical Economics, Montvale, NJ (2002):2696–2700.
  • POS VAR EL, RADULOVIC LL, CILLA DD Jr et al: Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. j Clin. Pharmacol (1996) 36:728–731.
  • MALTZ HC, BALOG DL, CHEIGH JS: Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann. Pharmacother. (1999) 33:1176–1179.
  • WENISCH C, KRAUSE R, FLADERER P et al.: Acute rhabdomyolysis after atorvastatin and fusidic acid therapy. Am. j Med. (2000) 109:78.
  • SIEDLIK PH, OLSON SC, YANG BB et al.: Erythromycin coadministration increases plasma atorvastatin concentrations. Pharmacol (1999) 39:501–504.
  • KANTOLA T, KIVISTO KT, NEUVONEN PJ: Effect of itraconazole on the pharmacokinetics of atorvastatin. Pharmacol Ther. (1998) 64:58–65.
  • MURDOCK DK, MURDOCK AK, MURDOCK RW et al: Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am. Heart J. (1999) 138:151–155.
  • HENRY K, MELROE H, HUEBESCH J et al.: Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet (1998) 352:1031–1032.
  • DUELL PB, CONNOR WE, ILLINGWORTH DR: Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am. J. Cardiol (1998) 81:368–369.
  • VAN JT, PAN J, WASTY T et al.: Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am. J. Cardiol (2002) 89:1306–1308.
  • TARASENKO LC: August 13, 2002 correspondence from Pfizer, Inc., US Medical Information.
  • BOYD RA, STERN RH, STEWART BH et al.: Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. j Clin. Pharmacol (2000) 40:91–98.
  • CLARKE TA, WASKELL LA: The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Dispos. (2003) 31:53–59.
  • LAU WC, WASKELL LA, WATKINS PB et al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 107:32–37.
  • WHITE CM: A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. j Cliii. Pharmacol (2002) 42:963–970.
  • HSIANG B, ZHU Y, WANG Z et al: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. j Biol. Chem. (1999) 274:37161–37168.
  • QUION JA, JONES PH: Clinical pharmacokinetics of pravastatin. Pharmacokiriet. (1994) 27:94–103.
  • NO AUTHORS LISTED: Pravachol° (pravastatin sodium). Bristol-Myers Squibb US prescribing information In: Physicians' Desk Reference (56th edn). Medical Economics, Montvale, NJ (2002):1099–1103.
  • REGAZZI MB, IACONA I, CAMPANA C et al.: Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplarih Proc. (1993) 25:2732–2734.
  • PARK JW, SIEKMEIER R, MERZ M et al: Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. Int. j Cliii. Pharmacol Ther. (2002) 40:439–450.
  • YOSHIMURA N, OKA T, OKAMOTO M et al.: The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation (1992) 53:94–99.
  • ALDERMAN CP: Possible interaction between nefazodone and pravastatin. Ann. Pharmacother. (1999) 33:871.
  • NO AUTHORS LISTED: Lescol° (fluvastatin sodium). Novartis US prescribing information. In: Physicians' Desk Reference (56th edn). Medical Economics, Montvale, NJ (2002):2361–2365.
  • FISCHER V, JOHANSON L, HEITZ F et al.: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P450 and implications for metabolic drug interactions. Drug Metab. Dispos. (1999) 27:410–416.
  • JACOBSON TA, AMOROSA LF: Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am. J Cardiol (1994) 73:D25–D29.
  • PAUCIULLO P, BORGNINO C, PAOLETTI R et al.: Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis (2000) 150:429–436.
  • FARNIER M, DEJAGER S: Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group. Am. I Cardiol (2000) 85:53–57.
  • PAPADAKIS JA, GANOTAKIS ES, JAGROOP IA et al.: Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int. j Cardiol (1999) 69:237–244.
  • SPENCE JD, MUNOZ CE, HENDRICKS L et al: Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am. I Cardiol (1995) 76:A80–A83.
  • SMIT JW, JANSEN GH, DE BRUIN TW et al.: Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. Am. I Cardiol (1995) 76:A126–A128.
  • ELIAV 0, SCHURR D, PFISTER P et al: High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia. Am. J. Cardiol (1995) 76:A76–A79.
  • LEITERSDORF E, MURATTI EN, ELIAV 0 et al: Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. Am. J Cardiol (1995) 76:A84–A88.
  • LEITERSDORF E, MURATTI EN, ELIAV 0 et al: Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination. Am. I Med. (1994) 96:401–407.
  • JARDINE A, HOLDAAS H: Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience. I Cliii. Pharm. Ther. (1999) 24:397–408.
  • FARNIER M, BARTOLINI M, SALKO T et al.: Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates. Am. j Cardiol (2003). In Press.
  • BAYS HE, DUJOVNE CA: Drug interactions of lipid-altering drugs. Drug Sal (1998) 19:355–371.
  • GOLDBERG R, ROTH D: Evaluation of fluyastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation (1996) 62:1559–1564.
  • HOLDAAS H et al: The use of statins after solid organ transplantation. I Nephrol Dial. Trariplant. (2002) 17(8):1537.
  • NO AUTHORS LISTED: Choice of lipid-regulating drugs. Med. Lett. Drugs Ther. (2001) 43:43–48.

Website

  • http://www.publiccitizen.org FISCHER C, WOLFE SM, SASICH L: Petition to the FDA to issue strong warnings about the potential for certain cholesterol-lowering drugs to cause potentially life-threatening muscle damage (2001). Accessed August 28 (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.